Q4 2017

Filed Apr 2, 2018 · 10-K · 92 days after period end · 0001493152-18-004567

Q4 2017 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—

Net Income

-$696.12K

derivedN/M vs Q4 2016

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Incomederived-$708,783N/M

Same quarter

Metric	Q4 2017derived from reported figures	Q4 2016derived from reported figures	Q4 2015
Revenue	—	$0.00	$0.00
Net Income	-$696.12K	-$556.08K	-$158.00K
EPS Diluted	—	—	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR